| Medical and Health Sciences | 2021-2025 | 618 | US 214 | 99.87 |
| Biological Sciences | 2021-2025 | 763 | US 174 | 99.20 |
| Clinical Biochemistry | Lifetime | 11 | US 8 | 99.73 |
| Surgery | Lifetime | 296 | US 166 | 99.75 |
| Epidemiology | Lifetime | 210 | US 107 | 99.73 |
| Infectious Diseases | Lifetime | 90 | US 46 | 99.72 |
| Microbiology | Lifetime | 326 | US 152 | 94.46 |
| Molecular Medicine | Lifetime | 211 | US 55 | 94.50 |
| Endocrinology | Lifetime | 416 | US 171 | 91.19 |
| Parasitology | Lifetime | 650 | US 258 | 85.93 |
| Applied Microbiology and Biotechnology | Lifetime | 251 | US 93 | 76.86 |
| Clinical Biochemistry | 2021-2025 | 1 | US 1 | 99.62 |
| Surgery | 2021-2025 | 51 | US 21 | 99.70 |
| Epidemiology | 2021-2025 | 232 | US 79 | 98.26 |
| Infectious Diseases | 2021-2025 | 306 | US 124 | 94.35 |
| Ecology | 2021-2025 | 899 | US 208 | 84.18 |
| Molecular Medicine | 2021-2025 | 132 | US 19 | 79.70 |
| Rehabilitation | 2021-2025 | 187 | US 59 | 78.61 |
| Applied Microbiology and Biotechnology | 2021-2025 | 114 | US 39 | 68.77 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 5 | US 4 | 99.91 |
| Orthopedic Infections and Treatments | Lifetime | 10 | US 7 | 99.88 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 23 | US 16 | 99.81 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 34 | US 17 | 99.83 |
| Bacterial biofilms and quorum sensing | Lifetime | 49 | US 23 | 99.57 |
| Cytomegalovirus and herpesvirus research | Lifetime | 83 | US 55 | 99.33 |
| Streptococcal Infections and Treatments | Lifetime | 56 | US 34 | 99.45 |
| Infectious Diseases and Tuberculosis | Lifetime | 55 | US 19 | 99.30 |
| Antibiotic Resistance in Bacteria | Lifetime | 196 | US 69 | 99.28 |
| Orthopaedic implants and arthroplasty | Lifetime | 210 | US 109 | 99.27 |
| Mycobacterium research and diagnosis | Lifetime | 204 | US 83 | 98.71 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 126 | US 66 | 98.81 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 313 | US 126 | 98.41 |
| Herpesvirus Infections and Treatments | Lifetime | 355 | US 229 | 98.07 |
| Antifungal resistance and susceptibility | Lifetime | 311 | US 130 | 98.28 |
| Molecular Biology Techniques and Applications | Lifetime | 396 | US 200 | 97.06 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 120 | US 34 | 96.53 |
| Antibiotic Use and Resistance | Lifetime | 463 | US 168 | 97.18 |
| Diphtheria, Corynebacterium, and Tetanus | Lifetime | 103 | US 41 | 94.63 |
| Microbial infections and disease research | Lifetime | 602 | US 217 | 96.38 |
| Antimicrobial Peptides and Activities | Lifetime | 687 | US 204 | 95.43 |
| Total Knee Arthroplasty Outcomes | Lifetime | 975 | US 438 | 97.20 |
| Polyomavirus and related diseases | Lifetime | 594 | US 280 | 95.58 |
| Clinical Laboratory Practices and Quality Control | Lifetime | 159 | US 62 | 94.39 |
| SARS-CoV-2 detection and testing | Lifetime | 727 | US 192 | 91.27 |
| Surgical site infection prevention | Lifetime | 492 | US 253 | 93.08 |
| Bacillus and Francisella bacterial research | Lifetime | 864 | US 437 | 89.63 |
| Antimicrobial agents and applications | Lifetime | 572 | US 99 | 89.23 |
| Infections and bacterial resistance | Lifetime | 366 | US 90 | 87.69 |
| Planarian Biology and Electrostimulation | Lifetime | 287 | US 118 | 87.72 |
| Otolaryngology and Infectious Diseases | Lifetime | 547 | US 211 | 83.95 |
| Legionella and Acanthamoeba research | Lifetime | 957 | US 340 | 81.82 |
| Bartonella species infections research | Lifetime | 546 | US 201 | 76.26 |
| Actinomycetales infections and treatment | Lifetime | 741 | US 181 | 74.14 |
| Medical Device Sterilization and Disinfection | Lifetime | 951 | US 358 | 66.46 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 1 | US 1 | 99.83 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 6 | US 2 | 99.30 |
| Orthopedic Infections and Treatments | 2021-2025 | 11 | US 5 | 99.71 |
| Orthopaedic implants and arthroplasty | 2021-2025 | 52 | US 27 | 98.84 |
| Infective Endocarditis Diagnosis and Management | 2021-2025 | 72 | US 32 | 98.99 |
| Microbial infections and disease research | 2021-2025 | 37 | US 8 | 95.99 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 196 | US 29 | 97.29 |
| Bacteriophages and microbial interactions | 2021-2025 | 214 | US 54 | 94.69 |
| Bacterial biofilms and quorum sensing | 2021-2025 | 171 | US 22 | 93.77 |
| Total Knee Arthroplasty Outcomes | 2021-2025 | 390 | US 165 | 95.86 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 275 | US 72 | 90.51 |
| Antimicrobial agents and applications | 2021-2025 | 201 | US 11 | 83.69 |
| Mycobacterium research and diagnosis | 2021-2025 | 822 | US 186 | 84.07 |
| Urinary Tract Infections Management | 2021-2025 | 605 | US 202 | 81.81 |
| Streptococcal Infections and Treatments | 2021-2025 | 611 | US 142 | 80.52 |
| Infectious Diseases and Tuberculosis | 2021-2025 | 469 | US 87 | 80.35 |
| Clinical Laboratory Practices and Quality Control | 2021-2025 | 102 | US 20 | 80.59 |
| Legionella and Acanthamoeba research | 2021-2025 | 524 | US 101 | 49.12 |
| Actinomycetales infections and treatment | 2021-2025 | 258 | US 37 | 42.85 |
| Diphtheria, Corynebacterium, and Tetanus | 2021-2025 | 386 | US 49 | 32.11 |
